Compare HZO & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HZO | BCYC |
|---|---|---|
| Founded | 1998 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 550.9M | 476.6M |
| IPO Year | 1998 | 2019 |
| Metric | HZO | BCYC |
|---|---|---|
| Price | $28.76 | $6.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $34.00 | $18.73 |
| AVG Volume (30 Days) | ★ 275.2K | 247.3K |
| Earning Date | 01-30-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,309,288,000.00 | $28,339,000.00 |
| Revenue This Year | $2.11 | N/A |
| Revenue Next Year | $4.03 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.85 | $6.03 |
| 52 Week High | $33.28 | $14.95 |
| Indicator | HZO | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 72.70 | 43.09 |
| Support Level | $27.25 | $6.37 |
| Resistance Level | $29.28 | $6.88 |
| Average True Range (ATR) | 1.16 | 0.32 |
| MACD | 0.35 | -0.02 |
| Stochastic Oscillator | 90.80 | 23.63 |
MarineMax Inc is a United-States-based company that sells new and used recreational boats under premium brands, and related marine products, like engines, parts, and accessories. The company is also engaged in other businesses, including providing services of repair, maintenance, and storage; managing related boat financing, insurance, and others; offering brokerage sales of boats and yachts; and operating a yacht charter business. The reportable segments of the company are Retail Operations and Product Manufacturing. The Retail Operations segment generates the majority of the company's revenue. The sale of new and used boats accounts for the majority of the company's total revenue. It serves customers across the U.S and international market.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.